Premium
Effects of pegylated interferon‐α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B
Author(s) -
Ren Hong,
Huang Yan
Publication year - 2019
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.13150
Subject(s) - medicine , hepatocellular carcinoma , hbsag , pegylated interferon , seroconversion , hbeag , hepatitis b virus , hepatitis b , combination therapy , oncology , immunology , chronic hepatitis , gastroenterology , virus , ribavirin
Abstract Chronic hepatitis B virus ( HBV ) infection continues to pose a serious global health threat and a significant socio‐economic burden in many areas of the world. Almost all current clinical practice guidelines on the management of chronic hepatitis B ( CHB ) infection recommend that eligible patients pursue the optimal treatment endpoint, which is defined as HB sAg loss with or without anti‐ HB s seroconversion. This review describes the effects of various regimens containing pegylated interferon (peg‐ IFN )‐alpha on functional cure and the outcome of hepatocellular carcinoma ( HCC ) in patients with CHB . Peg‐ IFN ‐α monotherapy is a treatment option recommended by local and international clinical practice guidelines to help more CHB patients achieve a sustained off‐treatment virological response, which is particularly appropriate for relatively young patients who demand a finite treatment approach. Peg‐ IFN ‐α add‐on or sequential therapy in patients who have achieved a suppressed viral load after nucleos(t)ide analog ( NA ) therapy may offer further benefits on HB eAg seroconversion and HB sAg decline, although the effects of de novo combination therapy with peg‐ IFN ‐α and NA s on long‐term outcomes remain unclear. Evaluation of baseline and on‐treatment predictors is useful for selecting the patients who are likely to achieve additional benefits. Furthermore, some recent studies have shown that peg‐ IFN ‐α–based therapy results in better prevention of HBV ‐related hepatocellular carcinoma ( HCC ), especially in high‐risk patients.